Sort
78,016 grants matching “breast cancer”
AXL-TARGETING ANTIBODY-DRUG CONJUGATE AS A NOVEL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER
$675,383University Of Southern California · · FY2019 · Defense Health Agency
Immuno-Isolating capsule for delivery of cell-based therapy for restoration of ovarian endocrine function in an animal model
$675,370Ariella Shikanov · University Of Michigan At Ann Arbor · R01 · FY2022 · HD
CHARGE consortium: gene discovery for CVD and aging phenotypes
$675,343Bruce M Psaty · University Of Washington · R01 · FY2021 · HL
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
$675,289Anna Karolina Palucka · Jackson Laboratory · R01 · FY2021 · CA
Improving Outcomes in the Breast Cancer Screening and Diagnostic Continuum
$675,237Christoph I Lee · University Of Wisconsin-Madison · R01 · FY2025 · CA
Identifying and validating novel susceptibility genes for breast cancer
$675,236Fergus Joseph Couch · Mayo Clinic Rochester · R01 · FY2016 · CA
A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence
$675,231Tara B Sanft · Yale University · R01 · FY2017 · CA
Phytoestrogens and Progression of Atherosclerosis
$675,141Howard N Hodis · University Of Southern California · U01 · FY2008 · AT
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
$675,112Tal Danino · Columbia Univ New York Morningside · R01 · FY2021 · EB
Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response
$675,099Janice L Brissette · Suny Downstate Medical Center · R01 · FY2021 · CA
Targeted degradation of RNAs by using small molecules
$675,077Matthew D Disney · Scripps Florida · R01 · FY2021 · CA
Quorum: glycopeptide discovery via mass spectrometry and spectral networking
$675,037Anand Patel · Abterra Biosciences, Inc. · R44 · FY2021 · GM
A NOVEL APPROACH TO INHIBIT THE IGF-I RECEPTOR SIGNALING PATHWAY FOR TREATMENT OF BREAST CANCER
$675,000Board Of Regents Of Nevada System Of Higher Education · · FY2009 · Department of Defense
MYELOPEROXIDASE IN THE PROGRESSION OF BREAST CANCER
$675,000Torrey Pines Institute For Molecular Studies, Inc. · · FY2009 · Department of the Army
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts
$674,979Brian L Sprague · University Of Vermont & St Agric College · R01 · FY2021 · CA
EARLY DIAGNOSIS OF CANCER: THE CANFIND CONSORTIUM
$674,903Genetica, Inc. · U01 · FY2001 · CA
Medicaid data as a complement to cohort studies for investigating cancers among older people with HIV
$674,794Corinne E. Joshu · Johns Hopkins University · R01 · FY2022 · CA
Computer-Aided Diagnosis of Pulmonary Embolism
$674,769Jianming Liang · Arizona State University-Tempe Campus · R01 · FY2017 · HL
METROPOLITAN NEW YORK REGISTRY OF BREAST CANCER FAMILIES
$674,634Columbia University Health Sciences · U01 · FY2000 · CA
Statistical Informatics for Cancer Research
$674,624Xihong Lin · Harvard School Of Public Health · P01 · FY2010 · CA
MOLECULAR CHANGES ASSOCIATED WITH INITIAL STEPS OF BREAST CANCER METASTASIS FOR RISK STRATIFICATION AND THERAPY DEVELOPMENT
$674,547Portland Va Research Foundation, Inc. · · FY2016 · Department of the Army
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
$674,537Timothy A Marlowe · Faknostics, Llc · R42 · FY2021 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab
$674,466Jason S Lewis · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes
$674,452Aniket A Kawatkar · Kaiser Foundation Research Institute · R01 · FY2024 · HL
Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
$674,416Aminah Jatoi · Mayo Clinic Rochester · K12 · FY2023 · CA